Abstract |
The antibiofilm activity of oritavancin in combination with rifampin, gentamicin, or linezolid was evaluated against 10 prosthetic joint infection (PJI)-related methicillin-resistant Staphylococcus aureus (MRSA) isolates by time-kill assays. Oritavancin combined with rifampin demonstrated statistically significant bacterial reductions compared with those of either antimicrobial alone for all 10 isolates (P ≤ 0.001), with synergy being observed for 80% of the isolates. Oritavancin and rifampin combination therapy may be an option for treating MRSA PJI.
|
Authors | Qun Yan, Melissa J Karau, Yash S Raval, Robin Patel |
Journal | Antimicrobial agents and chemotherapy
(Antimicrob Agents Chemother)
Vol. 62
Issue 10
(10 2018)
ISSN: 1098-6596 [Electronic] United States |
PMID | 30012765
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2018 American Society for Microbiology. |
Chemical References |
- Gentamicins
- Lipoglycopeptides
- Linezolid
- oritavancin
- Rifampin
|
Topics |
- Biofilms
(drug effects)
- Gentamicins
(pharmacology)
- Linezolid
(pharmacology)
- Lipoglycopeptides
(pharmacology)
- Methicillin-Resistant Staphylococcus aureus
(drug effects)
- Microbial Sensitivity Tests
- Rifampin
(pharmacology)
|